![](https://endpts.com/wp-content/uploads/2023/02/Robert-Ang-Vor-tile.jpg)
Robert Ang, Vor Biopharma CEO
Putting a twist on targeted therapy, Vor Biopharma heralds proof of concept for its gene-edited stem cells
Normally in a first-in-human clinical trial, researchers are looking to find the right dose of their experimental drug. Vor Biopharma set out to do something …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.